Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galderma Laboratories, a fully-integrated specialty pharmaceutical company, has announced the availability of Epiduo gel 0.1%/2.5%, the first and only, once-daily, topical acne treatment that combines the well-tolerated retinoid adapalene, and benzoyl peroxide, a well-known antimicrobial with no evidence of promoting bacterial resistance.
Subscribe to our email newsletter
The new prescription acne treatment received approval from the FDA in December, 2008 and will be on pharmacy shelves in the US in the first quarter of 2009.
According to the company, Epiduo gel treats both inflammatory and non-inflammatory lesions with no evidence of promoting antibiotic resistance, simplifying the management of mild-to-moderate acne. Additionally, Epiduo gel also helps reduce the complexity of acne management by reducing the number of medications a patient has to remember to take on a daily basis, potentially increasing treatment adherence.
Albert Draaijer, president, Americas, Galderma Laboratories, said: “The recent FDA approval and upcoming availability of Epiduo gel are examples of Galderma’s strong R&D capabilities and our ongoing commitment to providing innovative treatment options to patients.”